Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioStem Technologies Inc (ID) BSEM

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the... see more

Bullboard (OTCID:BSEM)

View:
User Avatar Image
(17)
•••
  • KevinOlearyX
Comment by KevinOlearyon Apr 30, 2025 12:26pm

RE:Spectacular Revenue Growth

Are you missing the fact that Trump tariffs mean BSEM lost the deal they announced November 24? So the whole Cdn sector is permanently lost due to tariff uncertainty.  
User Avatar Image
(202)
•••
  • JuniorMiner2014X
Post by JuniorMiner2014on Jan 21, 2025 2:06pm

Spectacular Revenue Growth

Revenue up 794% in Q4 2024 versus Q4 2023.  That is incredible.  Expectations for continued explosive growth.  Profits up tenfold, what am I missing?  I would have expected a big ...more  
User Avatar Image
(16)
•••
  • stockpickmover1X
Post by stockpickmover1on Jun 27, 2024 11:34am

Huge Alert $BSEM Research Report

The MedTech sector is often overlooked but is just as innovative as many of the top tech names. Two massive multi-billion-dollar markets for its regenerative therapies position BioStem ...more